Aditxt Inc. (ADTX)vsAstraZeneca PLC (AZN)
ADTX
Aditxt Inc.
$0.00
-6.82%
HEALTHCARE · Cap: $9.48M
AZN
AstraZeneca PLC
$171.61
-3.85%
HEALTHCARE · Cap: $302.65B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 421471302% more annual revenue ($60.44B vs $14,340). AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
ADTX
Avoid33
out of 100
Grade: F
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADTX.
Margin of Safety
+2.2%
Fair Value
$194.36
Current Price
$171.61
$22.75 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 1094.0% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ADTX
The strongest argument for ADTX centers on Revenue Growth, Debt/Equity. Revenue growth of 1094.0% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ADTX
The primary concerns for ADTX are EPS Growth, Market Cap, Profit Margin.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
ADTX profiles as a hypergrowth stock while AZN is a mature play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.23 — expect wider price swings.
ADTX is growing revenue faster at 1094.0% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 33/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aditxt Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Aditxt Inc. is an innovative biotechnology company dedicated to transforming healthcare through its proprietary immune modulation and personalized medicine platform. Focused on enhancing immune responses to address chronic diseases and allergies, Aditxt aims to significantly improve patient outcomes. With a robust pipeline of therapeutic candidates supported by comprehensive research and strategic collaborations, the company is poised to be a leader in the rapidly evolving field of immune-based therapies. Aditxt's commitment to scientific advancement and patient-centric solutions positions it at the forefront of immunology and the broader healthcare landscape.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?